The estimated Net Worth of Ruthann De Pietro is at least $4.59 Millón dollars as of 4 September 2012. Ruthann Pietro owns over 1,000 units of Insulet stock worth over $4,406,803 and over the last 17 years Ruthann sold PODD stock worth over $185,369.
Ruthann has made over 21 trades of the Insulet stock since 2011, according to the Form 4 filled with the SEC. Most recently Ruthann exercised 1,000 units of PODD stock worth $5,940 on 4 September 2012.
The largest trade Ruthann's ever made was exercising 10,819 units of Insulet stock on 20 January 2012 worth over $64,265. On average, Ruthann trades about 1,753 units every 15 days since 2008. As of 4 September 2012 Ruthann still owns at least 19,351 units of Insulet stock.
You can see the complete history of Ruthann Pietro stock trades at the bottom of the page.
Ruthann's mailing address filed with the SEC is C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD, MA, 01730.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman y Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: